Loading
MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2.
Open Targets scores its association with cancer at 0.57 (direct and indirect evidence; datatypes clinical 0.06, affected pathway 0.89, literature 0.89, genetic association 0.00, animal model 0.34).
In plain words · MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
MAPK9 (Mitogen-activated protein kinase 9) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and clinical evidence ties its variants to diagnosis, prognosis or drug response.
Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death.
No product in this corpus aims at MAPK9 yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA MAPK9: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 16 nTPM); high antibody staining in 23 normal tissues; highest cancer staining liver cancer (3 of 12 high). Distribution: no corpus cancer carries a prevalence row, threshold or catalogue link for it; Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas MAPK9 tissue; Open Targets ENSG00000050748 associations
First described 1994. Earliest sequence paper UniProt cites for the protein: Sluss H.K. et al, Mol. Cell. Biol, 1994, "Signal transduction by tumor necrosis factor mediated by JNK protein kinases". Source.
Sources: HGNC HGNC:6886 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P45984 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000050748 (association with cancer (MONDO_0004992) 0.57; (GraphQL API, CC0))
Serine/threonine-protein kinase involved in various processes such as cell proliferation, differentiation, migration, transformation and programmed cell death. Extracellular stimuli such as pro-inflammatory cytokines or physical stress stimulate the stress-activated protein kinase/c-Jun N-terminal kinase (SAP/JNK) signalling pathway. In this cascade, two dual specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 phosphorylate and activate MAPK9/JNK2. In turn, MAPK9/JNK2 phosphorylates a number of transcription factors, primarily components of AP-1 such as JUN and ATF2 and thus regulates AP-1 transcriptional activity. In response to oxidative or ribotoxic stresses, inhibits rRNA synthesis by phosphorylating and inactivating the RNA polymerase 1-specific transcription initiation factor RRN3. Promotes stressed cell apoptosis by phosphorylating key regulatory factors including TP53 and YAP1. Location: Cytoplasm; Nucleus (UniProt). Locus 5q35.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 16 nTPM).
Medium: Appendix, Fallopian tube, Lung, Oral mucosa, Prostate, Salivary gland, Skin, Spleen.
Medium only: breast cancer, carcinoid, cervical cancer, colorectal cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"MAPK9" OR ABSTRACT:"MAPK9" OR TITLE:"mitogen-activated protein kinase 9" OR ABSTRACT:"mitogen-activated protein kinase 9" OR TITLE:"Mitogen-activated protein kinase 9" OR ABSTRACT:"Mitogen-activated protein kinase 9" OR TITLE:"JNK2" OR ABSTRACT:"JNK2" OR TITLE:"p54a" OR ABSTRACT:"p54a" OR TITLE:"PRKM9" OR ABSTRACT:"PRKM9") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MAPK9, not a curated reading list.